ArticleFrontiers in pharmacology2026
Proton pump inhibitors and the risk of hospital acquired clostridioides difficile infection in critically ill patients.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Proton pump inhibitors (PPIs) are commonly prescribed medications for critically ill patients. However, the existence of a clear association between PPI prescriptions and Clostridioides difficile infection (CDI) remains controversial. This study aims to investigate the relationship between PPI use and CDI, thereby providing additional evidence for the clinical application of PPIs. Methods: This study extracted data from the eICU and MIMIC IV databases, ultimately enrolling 26,090 patients. Propensity score matching was employed to balance covariates across groups. Clinical outcomes were compared using χ Results: Compared with the non-PPI group, the PPI group showed a significantly increased risk of CDI (PPI vs. No-PPI: 2.6% vs. 1.6%; OR, 1.70; 95% CI, 1.43-2.02; p < 0.001). Across all subgroups, the risk of CDI was significantly higher in the PPI group than in the non-PPI group. Obesity (BMI ≥ 30), cancer, diabetes, IBD, kidney disease, and use of high-risk antibiotics were significantly associated with increased CDI risk in patients. Conclusion: Among critically ill patients, PPI recipients exhibited a significantly increased risk of CDI compared to those not using PPIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.